Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002142 · ClinicalTrials.gov registry record · NA
An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS
A NA study, sponsored by Gilead Sciences.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT00002142 is a NA study that has completed, run by Gilead Sciences. The registered enrollment target is 100 participants.
The verdict
NCT00002142, a NA study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerance of cidofovir (HPMPC) infusions in AIDS patients with relapsing cytomegalovirus (CMV) retinitis. To determine the time to retinitis progression in this patient population. To evaluate the impact of cidofovir therapy on visual acuity.
Interventions
- DRUG Probenecid
- DRUG Cidofovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002142
The ClinicalTrials.gov registry entry for NCT00002142 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Probenecid is the first listed.
NCT00002142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002142 about?
NCT00002142 is a clinical study titled "An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS". To evaluate the safety and tolerance of cidofovir (HPMPC) infusions in AIDS patients with relapsing cytomegalovirus (CMV) retinitis. To determine the time to retinitis progression in this patient population. To evaluate the impact of cidofovir therapy on visual acuity.
What is the current status of trial NCT00002142?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants.
What interventions are being tested in trial NCT00002142?
The interventions under investigation include: Probenecid (DRUG), Cidofovir (DRUG).
Who is sponsoring clinical trial NCT00002142?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.